PARACHUTE China Approval Trial
PARACHUTE China: Multi-center, Prospective, Single-arm Clinical Evaluation of the Safety and Efficacy of the Parachute Percutaneous Left Ventricle Partitioning System
Sponsor: CardioKinetix, Inc
Terminated
Company closed
Other terminated trials from CardioKinetix, Inc
- Heart Failure · Phase PHASE3 · Jun 2017
- Heart Failure · Jun 2017
- Congestive Heart Failure · Phase PHASE3 · Jun 2017
- Heart Failure · Jun 2017
- Heart Failure · Jun 2017
More terminations from CardioKinetix, Inc
This NA trial investigates Ischemic Heart Failure and is currently terminated or withdrawn. CardioKinetix, Inc leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Jun 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CardioKinetix, Inc
- Guangzhou Chuangsi Medical Technology Co., Ltd.
- Peking University
For direct contact, visit the study record on ClinicalTrials.gov .